Newer approach to understand cancer:
We now consider cancer as a systems biology disease, not just a
disease of genetics. Depending on what numbers we use, 12 to 18 percent
of cancers are familial or hereditary—which means the rest of them are
not. They are somatic, in that the mutations that cause the cancer arise
during a person's lifetime. So there's something about people’s biology
that either predisposes them to cancer or keeps them healthy.
# At its root, cancer is a disease of the DNA. But to cure it, we need to move beyond genetics and work together to uncover cancer’s deeper cellular chemistry, says Ronnie Andrews, President, Genetic and Medical Sciences at Life Technologies. Scientific American spoke with Andrews* about this new approach to combat cancer in the 21st century.
*thankfully shared from a blog by Ronnie Andrews - 11/11/13
: file:///E:/cancer-reconceptualized.html
Let's say the blueprint for a cancer is developed in a
downtown Los Angeles architectural firm. But the cell doesn’t become
cancerous unless the blueprint makes it to a manufacturing facility
located in Newport Beach. So the architects give their blueprint to a
courier who drives to Newport Beach and can get there one of many
different ways—if a road is blocked off somewhere, he can take a
different route. After the Human Genome Project, pharmaceutical
companies realized that they may not be able to change the blueprint for
cancer—as in, the genetic instructions for it—but they could
potentially block the highway system so that the courier couldn’t get to
the manufacturing center and deliver these instructions. By this we mean
that it might be possible to keep the cancer genome from being
transcribed—to prevent the "bad" proteins that create massive cell
production from ever being made.
Treating individual patient:
Let's say you get a biopsy of a person’s tumor and identify a handful
of cells of interest in that tumor. Then you do a whole genome sequence
analysis of those cells and see all of the multiple potential
mutational drivers of the cancer. At the same time, there are new
proteomic tools coming out that will show us in real great detail and
quantification not only what proteins are being produced, but where
they’re being produced in the cell.
Once we have all this information, what do we do? Let's go back to our
analogy. What we want to do is make a Google map of the patient's
cancer cells. Then a doctor could figure out where the courier is at any
point in time and pick drugs that stop the courier today by disrupting a
particular biochemical pathway. And, after identifying future off-ramps
that the courier might take, doctors could also prescribe drugs that
would thwart the cancer in the future.
 |
| http://ncip.nci.nih.gov/blog/bioinformatics/ |
Role of bioinformatics:
To find this perfect cocktail, you can imagine that a doctor would
flip open an iPad, log on to a portal and pull down his patient’s
information, which is password and HIPAA protected. Then he would relate
the data from his patient to outcomes from similar patients from the
past, whose details have been kept, anonymously, in a centralized
database. He'll be able to query the database and say, "show me 50
patients around the world that look like my patient at the genome and
protein level, and now show me the top protocols that have allowed for
the best survival rates for that patient." This is the power of
bioinformatics that we’re now all chasing. (*thankfully shared from a blog by Ronnie Andrews - 11/11/13
: file:///E:/cancer-reconceptualized.html)
No comments:
Post a Comment